You just read:

American Regent Announces Enrollment of First Patient in Phase 3 Trial to Investigate Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

News provided by

American Regent

Apr 24, 2017, 07:00 ET